These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 23960094)

  • 1. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
    Eich M; Roos WP; Nikolova T; Kaina B
    Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
    Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
    Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.
    Lozinski M; Bowden NA; Graves MC; Fay M; Day BW; Stringer BW; Tooney PA
    Oncotarget; 2024 Jan; 15():1-18. PubMed ID: 38227740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
    Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
    Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB.
    Aasland D; Götzinger L; Hauck L; Berte N; Meyer J; Effenberger M; Schneider S; Reuber EE; Roos WP; Tomicic MT; Kaina B; Christmann M
    Cancer Res; 2019 Jan; 79(1):99-113. PubMed ID: 30361254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
    Ramirez YP; Mladek AC; Phillips RM; Gynther M; Rautio J; Ross AH; Wheelhouse RT; Sakaria JN
    Mol Cancer Ther; 2015 Jan; 14(1):111-9. PubMed ID: 25351918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant.
    Bauer M; Goldstein M; Heylmann D; Kaina B
    PLoS One; 2012; 7(6):e39956. PubMed ID: 22768182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
    Ganesa S; Sule A; Sundaram RK; Bindra RS
    Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
    Zhang WB; Wang Z; Shu F; Jin YH; Liu HY; Wang QJ; Yang Y
    J Biol Chem; 2010 Dec; 285(52):40461-71. PubMed ID: 20880848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
    Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B
    Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.
    Chalmers AJ; Ruff EM; Martindale C; Lovegrove N; Short SC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1511-9. PubMed ID: 19931733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.
    Ito M; Ohba S; Gaensler K; Ronen SM; Mukherjee J; Pieper RO
    PLoS One; 2013; 8(5):e62351. PubMed ID: 23667469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.
    Knizhnik AV; Roos WP; Nikolova T; Quiros S; Tomaszowski KH; Christmann M; Kaina B
    PLoS One; 2013; 8(1):e55665. PubMed ID: 23383259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
    Peng C; Chen Z; Wang S; Wang HW; Qiu W; Zhao L; Xu R; Luo H; Chen Y; Chen D; You Y; Liu N; Wang H
    Cancer Res; 2016 Apr; 76(8):2340-53. PubMed ID: 26960975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
    Roos WP; Jöst E; Belohlavek C; Nagel G; Fritz G; Kaina B
    Cancer Res; 2011 Jun; 71(12):4150-60. PubMed ID: 21493591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
    Nadkarni A; Shrivastav M; Mladek AC; Schwingler PM; Grogan PT; Chen J; Sarkaria JN
    J Neurooncol; 2012 Dec; 110(3):349-57. PubMed ID: 23054561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
    Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
    Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
    Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
    Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.
    Cui B; Johnson SP; Bullock N; Ali-Osman F; Bigner DD; Friedman HS
    Mol Pharmacol; 2009 Jun; 75(6):1356-63. PubMed ID: 19261750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.